Ghent University Academic Bibliography

Advanced

Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2)

B Legros, Paul Boon UGent, P De Jonghe, B Sadzot, K Van Rijckevorsel and E Schmedding (2009) ACTA NEUROLOGICA SCANDINAVICA. 120(6). p.402-410
abstract
Objectives - (i) To describe the medical treatment of epilepsy in Belgium in 2006, (ii) to detect the presence or absence of consensus in epilepsy treatment and (iii) to analyze the evolution of the neurologists' opinion between 2003 and 2006. Materials and methods - In December 2006, 100 neurologists were interviewed with a structured questionnaire, based on ordinal four-point scales. The questionnaire contained questions on treatment choices in adult patients with epilepsy. The results of this survey were compared with results of a previous one done in 2003. Results - Initial monotherapy was the preferred treatment strategy. Valproate was first choice in idiopathic generalized epilepsy. Carbamazepine and oxcarbazepine were first choice in focal epilepsy with partial seizures. Valproate was also first choice in focal epilepsy with secondarily generalized seizures. New antiepileptic drugs were recommended in second line. However, in special treatment situations, they were considered first-line, e. g. lamotrigine in case of women in childbearing age. In comparison with 2003, there was a trend of using earlier the new antiepileptic drugs. Conclusions - In end 2006, carbamazepine, valproate and oxcarbazepine were considered to be first choice drugs, whereas other newer drugs, like lamotrigine, levetiracetam and topiramate were predominantly prescribed in second line.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
keyword
MYOCLONIC SEIZURES, REFRACTORY EPILEPSY, QSS SUBCOMMITTEES, IDIOPATHIC GENERALIZED EPILEPSY, TECHNOLOGY-ASSESSMENT SUBCOMMITTEE, QUALITY STANDARDS SUBCOMMITTEE, ACADEMY-OF-NEUROLOGY, NEWLY-DIAGNOSED EPILEPSY, NEW-ONSET EPILEPSY, AMERICAN-ACADEMY
journal title
ACTA NEUROLOGICA SCANDINAVICA
Acta Neurol. Scand.
volume
120
issue
6
pages
9 pages
publisher
WILEY-BLACKWELL PUBLISHING, INC
place of publication
MALDEN
Web of Science type
Article
Web of Science id
000271758800005
JCR category
CLINICAL NEUROLOGY
JCR impact factor
2.324 (2009)
JCR rank
78/165 (2009)
JCR quartile
2 (2009)
ISSN
0001-6314
DOI
10.1111/j.1600-0404.2009.01182.x
language
English
UGent publication?
yes
classification
A1
id
829152
handle
http://hdl.handle.net/1854/LU-829152
date created
2010-01-18 09:52:36
date last changed
2010-01-22 13:18:47
@article{829152,
  abstract     = {Objectives - (i) To describe the medical treatment of epilepsy in Belgium in 2006, (ii) to detect the presence or absence of consensus in epilepsy treatment and (iii) to analyze the evolution of the neurologists' opinion between 2003 and 2006. Materials and methods - In December 2006, 100 neurologists were interviewed with a structured questionnaire, based on ordinal four-point scales. The questionnaire contained questions on treatment choices in adult patients with epilepsy. The results of this survey were compared with results of a previous one done in 2003. Results - Initial monotherapy was the preferred treatment strategy. Valproate was first choice in idiopathic generalized epilepsy. Carbamazepine and oxcarbazepine were first choice in focal epilepsy with partial seizures. Valproate was also first choice in focal epilepsy with secondarily generalized seizures. New antiepileptic drugs were recommended in second line. However, in special treatment situations, they were considered first-line, e. g. lamotrigine in case of women in childbearing age. In comparison with 2003, there was a trend of using earlier the new antiepileptic drugs. Conclusions - In end 2006, carbamazepine, valproate and oxcarbazepine were considered to be first choice drugs, whereas other newer drugs, like lamotrigine, levetiracetam and topiramate were predominantly prescribed in second line.},
  author       = {Legros, B and Boon, Paul and De Jonghe, P and Sadzot, B and Van Rijckevorsel, K and Schmedding, E},
  issn         = {0001-6314},
  journal      = {ACTA NEUROLOGICA SCANDINAVICA},
  keyword      = {MYOCLONIC SEIZURES,REFRACTORY EPILEPSY,QSS SUBCOMMITTEES,IDIOPATHIC GENERALIZED EPILEPSY,TECHNOLOGY-ASSESSMENT SUBCOMMITTEE,QUALITY STANDARDS SUBCOMMITTEE,ACADEMY-OF-NEUROLOGY,NEWLY-DIAGNOSED EPILEPSY,NEW-ONSET EPILEPSY,AMERICAN-ACADEMY},
  language     = {eng},
  number       = {6},
  pages        = {402--410},
  publisher    = {WILEY-BLACKWELL PUBLISHING, INC},
  title        = {Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2)},
  url          = {http://dx.doi.org/10.1111/j.1600-0404.2009.01182.x},
  volume       = {120},
  year         = {2009},
}

Chicago
Legros, B, Paul Boon, P De Jonghe, B Sadzot, K Van Rijckevorsel, and E Schmedding. 2009. “Opinion of Belgian Neurologists on Antiepileptic Drug Treatment in 2006: Belgian Study on Epilepsy Treatment (BESET-2).” Acta Neurologica Scandinavica 120 (6): 402–410.
APA
Legros, B., Boon, P., De Jonghe, P., Sadzot, B., Van Rijckevorsel, K., & Schmedding, E. (2009). Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2). ACTA NEUROLOGICA SCANDINAVICA, 120(6), 402–410.
Vancouver
1.
Legros B, Boon P, De Jonghe P, Sadzot B, Van Rijckevorsel K, Schmedding E. Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2). ACTA NEUROLOGICA SCANDINAVICA. MALDEN: WILEY-BLACKWELL PUBLISHING, INC; 2009;120(6):402–10.
MLA
Legros, B, Paul Boon, P De Jonghe, et al. “Opinion of Belgian Neurologists on Antiepileptic Drug Treatment in 2006: Belgian Study on Epilepsy Treatment (BESET-2).” ACTA NEUROLOGICA SCANDINAVICA 120.6 (2009): 402–410. Print.